Search Results 391-400 of 16684 for alopecia
... alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. - Replacement ...
... alopecia) due to therapy administered prior to the initiation of study drug dosing. Nursing or pregnant women. Known allergy to any of the formulation ...
... alopecia is not an exclusion);. - Radiotherapy within 14 days prior to the first dose of NKX101, or not recovered from acute toxic effects of radiotherapy ...
Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. Ability and ...
... alopecia. Patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligible. Prior exposure to gemcitabine ...
Recovery to ≤ Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. * True abstinence ...
Vitiligo, alopecia, hypothyroidism on stable doses of thyroid replacement therapy, psoriasis not requiring systemic therapy within the past 2 years are ...
... alopecia; Radiation therapy within ≤ 14 days; Active or untreated brain metastases; History of carcinomatous meningitis; Uncontrolled concurrent malignancy ...
Patients with Grade 2 neuropathy or Grade 2 alopecia are eligible. Active idiopathic thrombocytopenic purpura. Active central nervous system (CNS) ...
Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. Subject must ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your World Cancer Day gift can go 4X as far.